StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their price target on Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating on the stock in a research note on Wednesday, August 7th.

Minerva Neurosciences Price Performance

Shares of NASDAQ:NERV opened at $2.61 on Wednesday. The company has a market capitalization of $18.25 million, a price-to-earnings ratio of -0.58 and a beta of 0.14. The business’s 50-day moving average is $2.74 and its 200-day moving average is $2.80. Minerva Neurosciences has a 1 year low of $2.26 and a 1 year high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Analysts anticipate that Minerva Neurosciences will post -2.26 EPS for the current year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.